David A. Siegel Stoke Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,500 shares of STOK stock, worth $174,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,500

Previous 19,700 26.4%

Holding current value

$174,435

Previous $266,000 33.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$12.24 - $15.92 $63,648 - $82,784	-5,200 Reduced 26.4%	14,500 $178,000
Q2 2024 Aug 14, 2024	BUY	$11.03 - $17.52 $217,291 - $345,144	19,700 New	19,700 $266,000
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $9,436 - $15,120	-2,800 Reduced 20.29%	11,000 $57,000
Q3 2023 Nov 14, 2023	BUY	$3.78 - $11.99 $52,164 - $165,462	13,800 New	13,800 $54,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $77,770 - $172,590	11,000 Added 42.97%	36,600 $337,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $87,920 - $157,710	7,000 Added 37.63%	25,600 $329,000
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $1,036 - $2,393	-100 Reduced 0.53%	18,600 $246,000
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $366,147 - $555,930	-21,300 Reduced 53.25%	18,700 $394,000
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $744,321 - $1.26 Million	-41,100 Reduced 50.68%	40,000 $960,000
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $792,275 - $1.15 Million	33,500 Added 70.38%	81,100 $2.06 Million
Q2 2021 Aug 16, 2021	BUY	$30.53 - $41.09 $702,190 - $945,070	23,000 Added 93.5%	47,600 $1.6 Million
Q1 2021 May 17, 2021	BUY	$36.08 - $69.81 $887,568 - $1.72 Million	24,600 New	24,600 $955,000

Others Institutions Holding STOK

# of Institutions

123

Shares Held

57.6M

Call Options Held

9.3K

Put Options Held

35.2K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $474M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account